# Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

> **NCT00101205** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Angioimmunoblastic T-cell Lymphoma
- B-cell Childhood Acute Lymphoblastic Leukemia
- B-cell Chronic Lymphocytic Leukemia
- Childhood Burkitt Lymphoma
- Childhood Diffuse Large Cell Lymphoma
- Childhood Grade III Lymphomatoid Granulomatosis
- Childhood Immunoblastic Large Cell Lymphoma
- Childhood Nasal Type Extranodal NK/T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Intraocular Lymphoma
- Noncutaneous Extranodal Lymphoma
- Peripheral T-cell Lymphoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Anaplastic Large Cell Lymphoma
- Recurrent Childhood Grade III Lymphomatoid Granulomatosis
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Small Noncleaved Cell Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent/Refractory Childhood Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Hairy Cell Leukemia
- Small Intestine Lymphoma
- T-cell Childhood Acute Lymphoblastic Leukemia
- T-cell Large Granular Lymphocyte Leukemia
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** oxaliplatin
- **DRUG:** etoposide

## Key facts

- **NCT ID:** NCT00101205
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** 2012-01
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101205, "Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00101205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*